Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 47 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

15%

7 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (4)
Early P 1 (1)
P 1 (20)
P 2 (11)
P 3 (7)

Trial Status

Recruiting17
Completed9
Not Yet Recruiting7
Active Not Recruiting7
Unknown4
Withdrawn3

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (47)

Showing 20 of 20 trials
NCT07562152Phase 3Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07026279Phase 1Active Not RecruitingPrimary

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

NCT07549958Phase 1Recruiting

PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

NCT06922591Phase 1Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT07491445Phase 3Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07049055Phase 1RecruitingPrimary

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT05642962Phase 1Active Not Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT04469556Phase 2CompletedPrimary

Pancreatic Adenocarcinoma Signature Stratification for Treatment

NCT07410676Phase 1Recruiting

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

NCT06615830Not Yet Recruiting

Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Cancer.

NCT06752811Phase 3RecruitingPrimary

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

NCT05827614Phase 1Active Not Recruiting

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

NCT06168812Phase 2Active Not Recruiting

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

NCT07342725Phase 1Not Yet RecruitingPrimary

Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

NCT06076837Phase 1Active Not RecruitingPrimary

The Seven Trial: Exploiting the Unfolded Protein Response

NCT07280377Phase 1Recruiting

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

NCT07201194Not ApplicableRecruiting

Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

NCT07230301Phase 2Not Yet RecruitingPrimary

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

NCT07231094Early Phase 1Not Yet RecruitingPrimary

A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer

NCT04467593Not ApplicableCompleted

Safety Study of Whole Body Hyperthermia for Advanced Cancer

Scroll to load more

Research Network

Activity Timeline